Sisram Medical Ltd. announced that its sublicensed-in botulinum toxin type A for injection, DaxibotulinumtoxinA-lanm (trademarked as DAXXIFY®), has passed quality testing from the National Institutes for Food and Drug Control of the People's Republic of China. The company stated that, as of the date of the announcement, DAXXIFY had not yet been launched for sale in Mainland China. However, Sisram Medical Ltd. has reached initial commercial orders for DAXXIFY in China, marking the commencement of its commercialization implementation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sisram Medical Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260105-11978642), on January 05, 2026, and is solely responsible for the information contained therein.